ACC 2023: Late-Breaking Science Video Collection

Published: 06 March 2023

  • Views:

    Views Icon 5653
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data. 

 

For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series

 

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

More from this programme

Part 3

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023. 

About the episode

ACC.23/WCC — In this succinct late-breaking science interview, Investigator, Dr Marielle Scherrer-Crosbie (Hospital of the University of Pennsylvania, US) discusses the results from the STOP-CA trial (Massachusetts General Hospital). This randomized phase II trial aims to investigate whether atorvastatin, a commonly prescribed statin drug for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin and prevent heart failure (NCT02943590). 

The results presented at ACC.23 showed that among study participants with lymphoma being treated with anthracyclines, the prophylactic use of atorvastatin over 12 months was associated with a lower rate of cardiac systolic dysfunction.

Questions:

  1. What unmet need does the STOP-CA trial aim to address?
  2. What is the existing evidence supporting the use of statins in this specific patient population?
  3. What is the trial design, patient population, and outcome measures?
  4. What are the key findings?
  5. What are the implications for patient care?
  6. What further research is needed?

Recoded on-site at ACC.23, New Orleans.

Faculty Biographies

Marielle Scherrer-Crosbie

Marielle Scherrer-Crosbie

Director

Dr Marielle Scherrer-Crosbie is the Director of the Echocardiography Laboratory at the Hospital of the University of Pennsylvania, Philadelphia, Philadelphia, US. Her main research interests are in the use of imaging and biomarkers in cardio-oncology both in human populations and in small animal models. She also uses small animal models in studying subclinical cardiac dysfunction in metabolic abnormalities.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.